ProCE Banner Activity

KEYNOTE-407: Phase III Trial of Carboplatin + Paclitaxel/Nab-Paclitaxel ± Pembrolizumab in Patients With Untreated Stage IV Squamous NSCLC

Slideset Download
Conference Coverage
Pembrolizumab addition to platinum-based chemotherapy significantly improved PFS and OS as first-line therapy for metastatic squamous NSCLC, with benefit demonstrated regardless of PD-L1 expression level.

Released: June 13, 2018

Expiration: June 12, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen